Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSA

Reliable liquid biopsy-based tools able to accurately discriminate prostate cancer (PCa) from benign prostatic hyperplasia (BPH), when PSA is within the “gray zone” (PSA 4–10), are still urgent. We analyzed plasma samples from a cohort of 102 consecutively recruited patients with PSA levels between...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Maurizia Mello-Grand, Antonino Bruno, Lidia Sacchetto, Simone Cristoni, Ilaria Gregnanin, Alessandro Dematteis, Andrea Zitella, Paolo Gontero, Caterina Peraldo-Neia, Riccardo Ricotta, Douglas M. Noonan, Adriana Albini, Giovanna Chiorino
Format:	article
Langue:	EN
Publié:	Frontiers Media S.A. 2021
Sujets:	SANIST-CIMS ceramide miR-5100 prostate cancer benign prostatic hyperplasia liquid biopsy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/62a2a94d6e1142f6afb3f836b01fc657
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSA

Documents similaires